Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

tion ratio.

"Zoticon is delighted that Sopherion Therapeutics LLC has accomplished its recruitment objectives for the Phase III registration trial in a timely and efficient manner, which can be directly attributed to the strength and quality of its management team," said Asher Nathan, Managing Director of Zoticon and Chairman of the Board of Sopherion Therapeutics LLC.

"Myocet has the potential to be a valued addition to the treatment of metastatic breast cancer," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "We look forward to reporting the efficacy results from this clinical trial after the required period of follow-up."

About Myocet(TM) (Nonpegylated Liposomal Doxorubicin)

Myocet is a liposome-encapsulated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome -- a manufactured, microscopic, vesicle consisting of discreet aqueous compartments surrounded by membranes composed of naturally occurring fats -- its distribution in the body is altered in such a way as to reduce doxorubicin's toxicity. Extensive clinical studies of Myocet in women with breast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering from advanced cancer, particularly in the metastatic stage. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion en
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... ... the FBRM® C35 particle size distribution technology in the particle characterization and material sciences ... 26-29 in Nuremberg, Germany. , ... (PRWEB) May 18, 2010 -- The Powtech/TechnoPharm jury awarded METTLER TOLEDO the ...
... Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading ... today announced that it reached an agreement to sell its RapidTrace ® ... Biotage AB for $16.5 million in cash.   , ... "Divesting these product lines is a ...
... (Nasdaq: SIAL ) will be presenting at the Baird,s 2010 Growth Stock ... ( 2:15 PM EDT ) in Chicago, IL.  Interested parties may ...  Users can click the "Webcast" icon to access this file.   , ... About Sigma-Aldrich: Sigma- Aldrich ...
Cached Biology Technology:FBRM C35 In-Process Particle Characterization Technology Receives Powtech/TechnoPharm Innovation Award 2010 2FBRM C35 In-Process Particle Characterization Technology Receives Powtech/TechnoPharm Innovation Award 2010 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 2Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 4Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010 2
(Date:4/24/2014)... decade-long effort by members of the International Glossina Genome ... of the tsetse fly, Glossina morsitans . The ... a potentially deadly disease endemic in sub-Saharan Africa. The ... new ways to prevent the disease and provide insights ... fly is quite unique in the insect world: it ...
(Date:4/24/2014)... New Rochelle, NY, April 24, 2014D-ribose is a ... nutritional supplement, and as a starting compound for ... of Escherichia coli to increase the ... step toward achieving more efficient industrial-scale production of ... in Industrial Biotechnology , a peer-reviewed journal ...
(Date:4/24/2014)... have identified the structural features that enable the ... endogenous RNAs in living cells. , When viruses ... and hijack cellular resources for the production of ... RNA molecules that are delivered directly to (in ... in the host cell, and provide the blueprints ...
Breaking Biology News(10 mins):Genetic code of the deadly tsetse fly unraveled 2Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3
... have discovered that mimecan and Thioredoxin Domain-Containing Protein ... The research article describing this work entitled Differential ... in Colorectal Adenoma and Cancer: A Proteomic Study ... of Experimental Biology and Medicine., Adenoma is the ...
... other fish in the rivers of Californias Central Valley ... researchers at Duke University and the National Oceanic and ... may serve as a cautionary tale to policymakers, scientists ... the construction of new dams in the region. ...
... of males than females are born worldwide every year. In ... than girls, there has been an apparent decline in the ... including Canada, Denmark, England, Germany, Japan and the United States. ... that can influence the probability of giving birth to a ...
Cached Biology News:A search for biomarkers for early detection of colorectal cancer 2New paper examines dams' effects on California salmon 2Weight gain between first and second pregnancies associated with increased odds of male second child 2